latest update:
[TrialBase DB]

trial summary · NCT07645469

FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia

Phase I Study of Autologous CD4+ and CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of MRD-Positive AML

Trial record from the TrialBase DB dataset, status RECRUITING, condition Acute Myeloid Leukemia, sponsored by Fred Hutchinson Cancer Center. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07645469phase PHASE1enrollment 9start 2026-12-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase I trial tests the safety, side effects and best dose of FH-WT1-E50 TCR T cells with azacitidine for the treatment of minimal residual disease (MRD) positive acute myeloid leukemia (AML). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize WT1, a protein on the surface of cancer cells. These WT1-specific T cells may help the body's immune system identify and kill WT1 cancer cells. Azacitidine is in a class of medications called antimetabolites. It works by stopping or slowing the growth of cancer cells. Giving FH-WT1-E50 TCR T Cells with azacitidine may be safe and/or effective for the treatment of MRD positive AML.

Source record: https://clinicaltrials.gov/study/NCT07645469

Facts

registry idNCT07645469
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1
study typeINTERVENTIONAL
lead conditionAcute Myeloid Leukemia
sponsorFred Hutchinson Cancer Center
sponsor classOTHER
enrollment9
start date2026-12-01
primary completion2030-07-19
completion2030-07-19
results postednot reported

Conditions

  • Acute Myeloid Leukemia

Interventions

  • Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells
  • Azacitidine
  • Biospecimen Collection
  • Bone Marrow Aspiration
  • Bone Marrow Biopsy
  • Chest Radiography
  • Computed Tomography
  • Echocardiography Test
  • Lumbar Puncture
  • Multigated Acquisition Scan
  • Positron Emission Tomography

Countries

  • United States

Intervention types: DRUG, PROCEDURE

Work with this record